FIGURE 4 Novel drug modalities for NRF2 activation Up to date, the only NRF2 activators in clinical use are DMF for MS (Rosito et al., 2020), and more recently Omaveloxolone, a semisynthetic terpenoid with potent NRF2-activating effects gained FDA approval in Februrary 2023 for the treatment of Friederichs ataxia (Boesch and Indelicato, 2024), a rare inherited neurodegenerative disease
Understanding what your semaglutide should look like also helps catch storage issues while traveling
It mimics a natural hormone that tells your brain you're full, slows down how quickly your stomach empties, and helps regulate blood sugar
Compounded medications are HSA and FSA eligible, providing additional cost flexibility
Beyond the medication, long-term success requires a holistic view of health
Baroreflex activation therapy with the Barostim device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials